CN1655675A - 利用三叶肽的联合治疗 - Google Patents

利用三叶肽的联合治疗 Download PDF

Info

Publication number
CN1655675A
CN1655675A CNA038120402A CN03812040A CN1655675A CN 1655675 A CN1655675 A CN 1655675A CN A038120402 A CNA038120402 A CN A038120402A CN 03812040 A CN03812040 A CN 03812040A CN 1655675 A CN1655675 A CN 1655675A
Authority
CN
China
Prior art keywords
trefoil
composition
trefoil peptide
chemotherapeutic agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038120402A
Other languages
English (en)
Chinese (zh)
Inventor
D·K·波多尔斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of CN1655675A publication Critical patent/CN1655675A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA038120402A 2002-03-26 2003-03-26 利用三叶肽的联合治疗 Pending CN1655675A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36757402P 2002-03-26 2002-03-26
US60/367,574 2002-03-26
US42270802P 2002-10-31 2002-10-31
US60/422,708 2002-10-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101808237A Division CN101152563A (zh) 2002-03-26 2003-03-26 利用三叶肽的联合治疗

Publications (1)

Publication Number Publication Date
CN1655675A true CN1655675A (zh) 2005-08-17

Family

ID=28678188

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038120402A Pending CN1655675A (zh) 2002-03-26 2003-03-26 利用三叶肽的联合治疗

Country Status (8)

Country Link
US (1) US20030186880A1 (cg-RX-API-DMAC10.html)
EP (1) EP1494530A4 (cg-RX-API-DMAC10.html)
JP (1) JP2005527547A (cg-RX-API-DMAC10.html)
CN (1) CN1655675A (cg-RX-API-DMAC10.html)
AU (1) AU2003224773B2 (cg-RX-API-DMAC10.html)
CA (1) CA2480372A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA04009363A (cg-RX-API-DMAC10.html)
WO (1) WO2003082196A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100381560C (zh) * 2005-09-27 2008-04-16 中国人民解放军第三军医大学第一附属医院 采用gs115酵母菌合成重组人肠三叶因子的工艺

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525018B1 (en) * 1999-05-17 2003-02-25 The General Hospital Corp. Treating eye disorders using intestinal trefoil proteins
US20030185838A1 (en) * 2001-11-28 2003-10-02 Podolsky Daniel K. Methods and compositions for treating lesions of the respiratory epithelium
US20030186882A1 (en) * 2001-07-31 2003-10-02 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
US20060189526A1 (en) * 2002-04-24 2006-08-24 Podolsky Daniel K Compositions containing an intestinal trefoil peptide and a mucoadhesive
US7538082B2 (en) 2001-04-24 2009-05-26 The General Hospital Corporation Methods and compositions for treating oral and esophageal lesions
US20040171544A1 (en) * 2001-04-24 2004-09-02 Barker Nicholas P. Trefoil domain-containing polypeptides and uses thereof
US20030105016A1 (en) * 2001-09-06 2003-06-05 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US20030181384A1 (en) * 2001-09-06 2003-09-25 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US20030185839A1 (en) * 2001-10-05 2003-10-02 Podolsky Daniel K. Methods and compositions for treating dermal lesions
JP2005508937A (ja) * 2001-10-05 2005-04-07 ザ ジェネラル ホスピタル コーポレーション 皮膚病変を治療するための方法および組成物
EP1581623A2 (en) * 2002-10-31 2005-10-05 The GI Company, Inc Trefoil domain-containing polypeptides and uses thereof
US20060188471A1 (en) * 2002-10-31 2006-08-24 Podolsky Daniel K Methods of treating epithelial lesions
US8075771B2 (en) * 2005-02-17 2011-12-13 E. I. Du Pont De Nemours And Company Apparatus for magnetic field gradient enhanced centrifugation
WO2013176785A1 (en) 2012-05-21 2013-11-28 The Trustees Of Columbia University In The City Of New York Trefoil family factor and uses thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
CA2994865A1 (en) 2015-09-09 2017-03-16 Fred Hutchinson Cancer Research Center Cartilage-homing peptides
WO2018049285A1 (en) 2016-09-09 2018-03-15 Fred Hutchinson Cancer Research Center Stable peptides and methods of use thereof
CA3049262A1 (en) 2017-01-18 2018-07-26 Fred Hutchinson Cancer Research Center Peptide compositions and methods of use thereof for disrupting tead interactions
CN110475565A (zh) 2017-03-16 2019-11-19 光明之火生物科学公司 软骨归巢肽缀合物及其使用方法
WO2018232122A1 (en) 2017-06-15 2018-12-20 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
JP7386161B2 (ja) 2017-12-19 2023-11-24 ブレイズ バイオサイエンス, インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
EP4137209A4 (en) * 2020-03-30 2023-08-30 Shandong Ruiying Pioneer Pharmaceuticals Co., Ltd. USE OF TFF2 PROTEIN AND IFN-? PROTEIN COMBINATION IN THE TREATMENT OF NOVEL CORONAVIRUS INFECTION

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US151472A (en) * 1874-06-02 Improvement in rotary engines
US4370317A (en) * 1980-09-10 1983-01-25 Novo Industri A/S Pancreatic spasmolytic polypeptide
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US6221840B1 (en) * 1991-02-14 2001-04-24 The General Hospital Corporation Intestinal trefoil proteins
US6063755A (en) * 1991-02-14 2000-05-16 The General Hospital Corporation Intestinal trefoil proteins
US5703047A (en) * 1992-09-21 1997-12-30 Board Of Regents, The University Of Texas System Methods and treatments for corneal healing with growth factors
DK6893D0 (da) * 1993-01-21 1993-01-21 Novo Nordisk As Peptid
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
HU226921B1 (en) * 1994-08-26 2010-03-01 Novo Nordisk As Trefoil peptide dimer
US6525018B1 (en) * 1999-05-17 2003-02-25 The General Hospital Corp. Treating eye disorders using intestinal trefoil proteins
US20030186882A1 (en) * 2001-07-31 2003-10-02 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
US20030185838A1 (en) * 2001-11-28 2003-10-02 Podolsky Daniel K. Methods and compositions for treating lesions of the respiratory epithelium
WO1999010377A1 (en) * 1997-08-25 1999-03-04 The General Hospital Corporation Receptor for intestinal trefoil factor
CA2341488A1 (en) * 1998-08-26 2000-03-09 Smithkline Beecham Corporation Therapies for treating pulmonary diseases
US6372439B2 (en) * 1998-10-01 2002-04-16 James R. Goldenring Screen for gastric adenocarcinoma
ES2272311T3 (es) * 1999-07-05 2007-05-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Suministro de peptidos trebol.
WO2001041779A2 (en) * 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
CA2391594A1 (en) * 1999-12-23 2001-06-28 Human Genome Sciences, Inc. Trefoil domain-containing polynucleotides, polypeptides, and antibodies
JP4822652B2 (ja) * 2000-11-22 2011-11-24 エンド ファーマシューティカルズ インコーポレイテッド 粘膜炎の治療
US7538082B2 (en) * 2001-04-24 2009-05-26 The General Hospital Corporation Methods and compositions for treating oral and esophageal lesions
EP1383527A4 (en) * 2001-04-24 2004-07-14 Gen Hospital Corp METHOD AND COMPOSITIONS FOR TREATING ORAL AND EYE EYE LESIONS
US20030105016A1 (en) * 2001-09-06 2003-06-05 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
JP2004534801A (ja) * 2001-06-14 2004-11-18 ノボ ノルディスク アクティーゼルスカブ Tff2ペプチドによる粘膜修復
US20030153496A1 (en) * 2001-06-14 2003-08-14 Lars Thim Mucosal repair by TFF dimer peptides
WO2003011117A2 (en) * 2001-07-31 2003-02-13 The General Hospital Corporation Methods and compositions for treating and preventing distal bowel lesions
US20030181384A1 (en) * 2001-09-06 2003-09-25 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
JP2005508937A (ja) * 2001-10-05 2005-04-07 ザ ジェネラル ホスピタル コーポレーション 皮膚病変を治療するための方法および組成物
US20030185839A1 (en) * 2001-10-05 2003-10-02 Podolsky Daniel K. Methods and compositions for treating dermal lesions
AU2002351181B2 (en) * 2001-11-28 2008-08-07 The General Hospital Corporation Methods and compositions for treating lesions of the respiratory epithelium
US20030215431A1 (en) * 2002-02-11 2003-11-20 Lars Thim Management of mucosal viscosity by TFF monomer peptides
US6780383B1 (en) * 2003-02-28 2004-08-24 Eugene Ettlinger System for sterilization of spaces and surfaces
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
CA2609143A1 (en) * 2005-05-18 2006-11-23 The Gi Company, Inc. Oral drug delivery system and methods of use thereof
WO2007014197A2 (en) * 2005-07-25 2007-02-01 The G.I. Company, Inc. Yeast expression vectors for production of itf

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100381560C (zh) * 2005-09-27 2008-04-16 中国人民解放军第三军医大学第一附属医院 采用gs115酵母菌合成重组人肠三叶因子的工艺

Also Published As

Publication number Publication date
AU2003224773A1 (en) 2003-10-13
JP2005527547A (ja) 2005-09-15
CA2480372A1 (en) 2003-10-09
EP1494530A2 (en) 2005-01-12
AU2003224773B2 (en) 2010-08-26
EP1494530A4 (en) 2009-06-24
WO2003082196A2 (en) 2003-10-09
WO2003082196A3 (en) 2003-12-04
US20030186880A1 (en) 2003-10-02
MXPA04009363A (es) 2005-01-25

Similar Documents

Publication Publication Date Title
CN1890371A (zh) 成纤维细胞生长因子的21突变蛋白
AU2003224773B2 (en) Combination therapy using trefoil peptides
CN1230966A (zh) 勒帕素拮抗剂在用于治疗ii型糖尿病胰岛素耐受性中的用途
CN1235611A (zh) 应用类胰高血糖素肽-1(glp-1)或类似物消除外科手术后的分解代谢改变
JP2023011857A (ja) 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法
CN1303381A (zh) 二肽基肽酶iv的新效应物
CN1520309A (zh) 治疗口腔及食道损伤的方法和组合物
CN1599619A (zh) 治疗真皮损伤的方法和组合物
CN1617739A (zh) 用于治疗呼吸道上皮病变的方法和组合物
CN1277553A (zh) 血管生成促进剂和血管生成增效剂
CN110204617B (zh) 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途
CN102741278A (zh) 新化合物及其对摄食行为的作用
CN1313149C (zh) 具有血管活性肠肽的生物学活性的化合物在治疗结节病中的用途
CN1541103A (zh) 诱导持续免疫应答的方法
CN1802158A (zh) 用于鼻给药的药物组合物
US20230295260A1 (en) Glp receptor agonists
CN1615154A (zh) 干扰素tau的口服给药
CN1178660C (zh) 抗病毒药物组合
CN1367686A (zh) 新组合物
HK1081401A (en) Combination therapy using trefoil peptides
CN1125081C (zh) 重组天然和新型人胰岛素及其制备方法
CN101039696A (zh) 给药人il-18治疗创伤的方法
KR19980064258A (ko) 항비만 단백질
CN1161464C (zh) 人表皮生长因子受体特异性融合蛋白及其应用
CN1684705A (zh) 使用具有preptin功能的化合物的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1081401

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050817

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1081401

Country of ref document: HK